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Abstract The aim of this study was to establish the preva-
lence of resistance to fluoroquinolones in Escherichia coli
strains isolated from patients undergoing transrectal
ultrasound-guided prostate biopsy (TRUS-Bx) and to evaluate
the incidence of possible infectious complications associated
with this procedure. One hundred and four patients undergo-
ing a TRUS-Bx in a single medical centre were prospectively
enrolled in this study. In all patients, pre-biopsy rectal swabs
were obtained. The analysis determined the antimicrobial sus-
ceptibility of E. coli strains to levofloxacin, ciprofloxacin and
a panel of other antibiotics. Before biopsy, each of the men
received a levofloxacin-based prophylaxis. Telephone follow-
up was used to identify patients who had complications after
TRUS-Bx. Fluoroquinolone-resistant strains were isolated
from 9.62 % of the patients. In all cases, there were related
to E. coli and all those strains were resistant to both
levofloxacin and ciprofloxacin. Fluoroquinolones showed
greater antimicrobial activity against E. coli (p<0.05) than
ampicillin, amoxicillin/clavulanate and cephalothin.Minor in-
fectious complications occurred in three patients (2.91 %).
The relation between the resistance of E. coli to
fluoroquinolones and the risk of readmission, as well as infec-
tious complications, was statistically significant (p<0.05). De-
spi te recent reports of increasing prevalence of
fluoroquinolone-resistant E. coli and the associated increase
of severe infectious complications, the presented results have
not conf i rmed th i s phenomenon . Res i s t ance to
fluoroquinolones of E. coli strains isolated from rectal swab
cultures prior to TRUS-Bx is the risk factor for readmission
and infectious complications after this procedure.
Introduction
Prostate cancer (PCa) is the most common non-skinmalignan-
cy among men in developed countries and, due to aging pop-
ulation, its incidence is steadily rising. Furthermore, despite
widely discussed overdiagnosis and overtreatment of PCa, it is
the second leading cause of cancer-related death in Western
men [1–3]. This argues for the need of an effective and safe
tool to diagnose this cancer conclusively. At present, system-
atic transrectal ultrasound-guided prostate biopsy (TRUS-Bx)
is the gold standard for histological diagnosis of PCa [4].
TRUS-Bx is considered to be one of the most frequently per-
formed urological procedures in the world. However, due to
the procedure of collecting the biopsy samples, this method is
fraught with relatively frequent complications [4]. The most
common of these condit ions are haematuria and
haematospermia, which are usually mild and do not require
any treatment [4, 5].
Much more significant consequences may result from the
infections caused by bacteria originating from the rectal flora.
The most common pathogen responsible for them is Gram-
negative Escherichia coli [6, 7]. In older studies, the incidence
of complications like febrile urinary tract infections (UTIs),
acute prostatitis or E. coli sepsis was low. However, in recent
years, many authors have reported a substantial increase of
infections in patients following TRUS-Bx [8–10].
Most of these conditions occur despite the use of
fluoroquinolones, which are usually the first-line antibiotics
in urological prophylaxis. The European Association of
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Urology (EAU) Guidelines on Prostate Cancer state that they
are the drugs of choice prior to TRUS-Bx [4, 11].
Fluoroquinolones is a class of synthetic antimicrobial agents
with known effective activity against Gram-negative bacteria.
However, many reports have documented the increasing exis-
tence of E. coli strains resistant to this group of antibiotics
[8–10]. This has led to criticism of a currently used antimicro-
bial prophylaxis [12–16].
Thus, the aim of this study was to establish the prevalence
of resistance to fluoroquinolones in E. coli strains isolated
from patients undergoing TRUS-Bx and to evaluate the inci-
dence of possible infectious complications associatedwith this
procedure.
Materials and methods
One hundred and four Caucasian males, with a median age of
65 years (range 49–87 years), undergoing a TRUS-Bx in a
single medical centre in Gdańsk, Poland, from August 2013
to August 2014, were enrolled in this prospective study.
All study patients had been instructed by the physician
regarding possible complications and provided informed con-
sent before prostate biopsy. Indications for TRUS-Bx includ-
ed an increased serum level of prostate-specific antigen
(PSA>4 ng/ml) and/or abnormal digital rectal examination
(DRE). Patients with a previous diagnosis of PCa and/or
self-reported allergy to fluoroquinolones were excluded from
the study.
The basic data including age, body mass index (BMI),
history of previous biopsies and antibiotic therapy (in the 3-
month period before TRUS-Bx) were collected.
Subsequently, in all patients, pre-biopsy rectal swabs were
obtained using a single cotton-tip applicator with agar gel
system (Deltalab, Spain). Within 4 h, samples were
transported to the microbiological laboratory and streaked on-
to Columbia agar (bioMérieux, France) with 5 % sheep blood
and MacConkey medium (bioMérieux, France). The plates
were incubated aerobically for 24 h at 37 °C. The bacterial
strains were identified using the biochemical method in an
automated analyser VITEK 2 (bioMérieux, France). The disc
diffusion method was used for antibiotic susceptibility testing
according to the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) criteria [17].
The analysis determined the antimicrobial susceptibility of
E. coli strains to levofloxacin, ciprofloxacin and a panel of
antibiotics, including ampicillin, amoxicillin/clavulanate,
cephalothin, cefuroxime, amikacin, trimethoprim/
sulphamethoxazole and nitrofurantoin.
Multiple drug resistance (MDR) was defined in this study
according to the criteria published by Magiorakos et al. as a
non-susceptibility to at least one agent in three or more anti-
microbial categories [18].
The results of rectal swab cultures in our study were
blinded until the last patient had completed follow-up, with
the exception of infectious complications.
After this procedure, each patient received a prescription
for a 3-day course of oral levofloxacin (500 mg once a day).
All patients were strictly advised to start prophylaxis using the
prescribed antibiotic 12 h before TRUS-Bx.
The prostate biopsies were carried out under local anaes-
thesia of 10 ml 2 % lignocaine. No enema was used and
patients were not obligated to fast before this procedure. Bi-
opsies were performed with the patient in the left decubital
position using an automated Pro-Mag biopsy gun (Manan
Medical Products, USA) with a disposable 16G biopsy needle
(M.D.L., Italy) in conjunction with a medical ultrasound con-
sole (BK Medical Ultrasound Scanner 1202 Flex Focus 400,
Herlev, Denmark). The specimens were taken from both the
lateral and the medial part of the prostate base, midgland and
apex. The median biopsy core number was 15 (range 7–16).
After TRUS-Bx, all patients were asked to return to the
study centre hospital if they had a fever higher than 38 °C,
severe pain, prolongated haematuria or exacerbation of lower
urinary tract symptoms. The decision for readmission in each
case was considered individually by a urological consultant.
Telephone follow-up with a response rate of 99.04 % was
used to identify patientswho had complicationswithin 14 days
after TRUS-Bx. The follow-up yes-or-no questions were re-
lated to complications described in the EAU guidelines
assigned to this procedure and included the following symp-
toms and conditions: haematospermia, haematuria>1 day,
rectal bleeding>2 days, urinary retention, fever>38 °C, pros-
tatitis, epididymitis, UTI, urosepsis and other complications
requiring hospitalisation or ambulatory treatment [4]. Infec-
tious complications were defined as the secondary conditions
that develop after TRUS-Bx and included fever, prostatitis,
epididymitis, UTI or urosepsis.
The trial data were entered into a specially designed secure
online database accessible only by the project team. The re-
sults were analysed with the statistical software MedCalc
(MedCalc Software, version 14.8.1, Belgium). Chi-square
analysis and Student’s t-tests were performed. Statistical sig-
nificance was defined as p<0.05.
The study was approved by the Local Research Ethics
Committee.
Results
E. coli was the most prevalent Gram-negative bacteria, with a
presence of 96.15 % of rectal swabs. Fluoroquinolone-
resistant strains were isolated from 9.62 % of patients. In all
cases, they were related to E. coli and all those strains were
resistant to both levofloxacin and ciprofloxacin.
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The percentage of patients with a previous history of
antibiotic treatment within the 3 months before TRUS-
Bx tends to be higher (40 %) in the fluoroquinolone-
resistant group than in the rest of the patients (13.83 %)
(p=0.1102).
Levofloxacin (and ciprofloxacin) showed greater antimi-
crobial activity against E. coli than ampicillin (p=0.0008),
amoxicillin/clavulanate (p=0.0339) and cephalothin (p=
0.0013, Fig. 1).
There were no differences between fluoroquinolones and
trimethoprim/sulphamethoxazole, amikacin or nitrofurantoin
on this point. All fluoroquinolone-resistant strains of E. coli
were susceptible to amikacin and cefuroxime (Fig. 2). The
relation between the resistance of E. coli to fluoroquinolones
and the risk of readmission (p=0.0123), as well as infectious
complications (p=0.0168), was statistically significant. There
was no correlation between fluoroquinolone resistance
and other compl ica t ions , l ike haematur ia and
haematospermia (Table 1).
In 10.58 % of all patients, we observedMDR E. coli strains
(60 % of which were resistant to fluoroquinolones). The pres-
ence of MDR strains was significantly associated with the risk
of rehospitalisation (p<0.0001), as well as the occurrence of
infectious complications (p=0.0042).
The most common complications after TRUS-Bx in
the study group were prolonged haematuria (>1 day)
(45.63 %) and haematospermia (14.56 %). Infectious
complications occurred in three patients (2.91 %).
Two of them had a fluoroquinolone-resistant E. coli
strain (Table 1).
Th r ee o f t he pa t i en t s r equ i r ed a sho r t - t e rm
rehospitalisation: two of them due to UTI with fever and one
because of congenital coagulopathy and haematuria. There
was no urosepsis after TRUS-Bx in the studied group.
The history of previous TRUS-Bx and the number of biop-
sy cores taken had no influence on the incidence rate of
complications.
Discussion
According to the EAU guidelines, oral or intravenous
fluoroquinolones are the state-of-the-art prophylaxis prior to
prostate biopsy [4, 11]. Due to the transrectal access used
during the biopsy, fluoroquinolones seem to be an effective
option, as their spectrum covers Gram-negative bacteria. Sev-
eral recent studies have underlined the growing incidence of
fluoroquinolones resistance that may lead to increased risk of
infectious complications after prostate biopsy. It is postulated
that the increased resistance to these antibiotics is related to
the widespread use of fluoroquinolones in everyday medical
practice [7].
We observe that a significant number of patients undergo-
ing TRUS-Bx had a previous history of antibiotic treatment
for various reasons. What is more, prescribing antibiotics for
men with a newly elevated PSA level, on the presump-
tion that the patient has prostatitis, is still a common
urological practice [19].
This phenomenon seems to be confirmed by the results of
our study, where 16.35 % of participants were taking antibi-
otics within the 3 months before biopsy. In the group of pa-
tients with E. coli strains resistant to fluoroquinolones, this
percentage was even more than three times as great as in the
remaining group (40 % vs. 13.83 %, Table 1). The results are
consistent with the publication by Steensels et al., who
showed that receiving fluoroquinolones before biopsy
significantly increased the risk of rectal colonisation by
these strains [15].
Fig. 1 Antibiotic susceptibility of Escherichia coli strains. Significant differences between levofloxacin/ciprofloxacin and other antibiotics are marked
with an asterisk (*), with p<0.05
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Rectal swab cultures analysis has shown that at least 90 %
of E. coli strains were sensitive to amikacin, cefuroxime,
nitrofurantoin and fluoroquinolones (levofloxacin and cipro-
floxacin) (Fig. 1). The results of our study do not support other
reports with a large percentage of E. coli strains resistant to
fluoroquinolones in patients undergoing TRUS-Bx. In rela-
tion to the data published by Liss et al. (18 %, California,
USA), S Taylor et al. (19.0 %, Vancouver, Canada), AK Tay-
lor et al. (19.6 %, Chicago, USA), Steensels et al. (22 %,
Leuven, Belgium) and Lee at al. (26.7 %, Jeonbuk Province,
Korea), our results are more than twice as low (9.62 %) [15,
20–23]. Only the results reported by Batura et al. (10.6 %
London, UK) appear comparable [24]. This indicates a signif-
icant geographical variation of fluoroquinolone-resistant
E. coli strains. This issue has also been discussed in the review
by Erb et al. in symptomatic patients, who noted a higher
prevalence of those strains in Latin American countries and
Spain than in patients from North America, Central Europe
and the British Isles [25].
Furthermore, all of the E. coli strains isolated from our
studied population demonstrated simultaneous insensitivity
to ciprofloxacin and levofloxacin. E. coli may acquire resis-
tance for both antibiotics in the same way. This appears to be
the result of one of three main mechanisms: development of
efflux (pumping drugs out of the cell), alterations in the fluo-
roquinolone enzymatic targets (e.g. DNA gyrase, topoisomer-
ase IV) or decreased outer membrane permeability. Therefore,
a selective resistance to one of these antibiotics is rare [26].
Fig. 2 Antibiotic susceptibility of fluoroquinolone-resistant E. coli strains. Significant differences between cefuroxime/amikacin and other antibiotics
are marked with an asterisk (*), with p<0.05
Table 1 Summary of the clinical data according to the fluoroquinolone resistance of Escherichia coli strains
Data Fluoroquinolone-resistant E. coli (+) Fluoroquinolone-resistant E. coli (−) Total
Number of patients 10 (9.62 %) 94 (90.38 %) 104 (100 %)
Average age 68.5 66.99 67.13
Average BMI 27.25 27.54 27.47
Antibiotics 3 months before TRUS-Bx 40 % 13.83 % 16.35 %
Previous TRUS-Bx 30 % 11.7 % 13.46 %
Average IPSS before TRUS-Bx 13.80 12.31 12.45
MDR* 60 % 5.32 % 10.58 %
Average prostate volume (ml) 40 46.66 46.02
Median PSA (ng/ml) 9.12 7.91 7.93
Readmission rate* 20 % 1.08 % 2.91 %
Infectious complications* 20 % 1.08 % 2.91 %
Haematuria 30 % 47.31 % 45.63 %
Haematospermia 0 16.12 % 14.56 %
BMI body mass index; TRUS-Bx transrectal ultrasound-guided prostate biopsy; IPSS International Prostate Symptom Score; MDR multiple drug
resistance; PSA prostate-specific antigen
Significant differences between groups are marked with an asterisk (*), with p<0.05
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Another problem in the acquisition of resistance by E. coli
is MDR. Those strains have become a major public health
issue in many countries and the main reason for treatment
failure of UTI [27]. Our results confirmed that the presence
of MDR E. coli strains in faecal carriage is a risk factor for
readmission after TRUS-Bx due to infectious complications.
The case–control study by Carignan et al. showed a signif-
icantly increased rate of infectious complications after prostate
biopsy, from 0.52 % in 2002–2009 to 2.15 % in 2010–2011,
despite prophylaxis [16]. In 2006, Davidson et al. first report-
ed MDR E. coli-related sepsis following transrectal prostate
biopsy [28]. Since then, many researchers have been trying to
find alternative methods of prostate cancer diagnosis. One of
the possibilities is transperineal biopsy, which still has some
limitations, including: increased time, need for longer training
and financial constraints, as well as the need for general or
spinal anaesthesia. Furthermore, the necessary equipment for
transperineal biopsy is not widely available. That makes it a
marginally performed procedure in comparison with
TRUS-Bx [29].
The increase of prostate biopsy-related infectious compli-
cations also justifies the need to search for new effective pre-
vention schemes. A number of antibiotic prophylaxis modifi-
cations have been proposed. These include the use of other
fluoroquinolones (from second and third generation) in vari-
ous oral and intravenous doses, changes of antibiotic classes
(like aminoglycosides, sulfonamides or even carbapenems) or
different lengths of prophylaxis [13, 30, 31]. However, none
of these methods has solved the issue with prostate biopsy-
related infections.
One of the potential ways to decrease TRUS-Bx-related
infectious complications is to use targeted antimicrobial pro-
phylaxis. Performing rectal swabs culture prior TRUS-Bx can
identify carriers of E. coli strains resistant to fluoroquinolones
and choose proper prophylactic antibiotics [21]. In 2010,
Batura et al. reported a strong correlation between the antimi-
crobial susceptibility of rectal swabs collected before TRUS-
Bx and cultures from blood and urine [24]. These cultures
provide useful data for selecting appropriate antibiotics for
prophylaxis and treatment of infections associated with pros-
tate biopsy.
All the patients in our study received levofloxacin prior to
TRUS-Bx, besides the results of rectal swab cultures. This
enabled to determine the effectiveness of currently used rou-
tine regimens of antimicrobial prophylaxis.
The group of patients with rectal flora resistant to
fluoroquinolones showed a significantly higher risk of devel-
oping infectious complications and readmission (Table 1).
However, the potential benefit of targeted antibiotic prophy-
laxis could refer only to 1 of 52 men who underwent rectal
swab culture before prostate biopsy. The result is even less
favourable than that published by Taylor et al. (1/38) and is
probably related to lower rates of resis tance to
fluoroquinolones [21]. This rate may grow along with the
increase in the incidence of MDR E. coli strains in the popu-
lation. It should also be taken into account that the rectal swab
cultures do not always correspond to the pathogen isolated
from urine (or blood) in the case of infectious complications.
In our group, this situation occurred in 1 of 3 patients who
developed infectious complications. Kim et al. showed that all
four of their patients who developed fever after TRUS-Bx had
fluoroquinolone-sensitive rectal flora [32]. Furthermore, none
of the patients presented in this study (233 men) developed
urosepsis. The authors explained it by the potentially small
study group. This could also be the reason for the absence of
such severe complications in our study; the average number of
patients developing urosepsis after TRUS-Bx despite prophy-
laxis was between 0.3 and 2.8 %. Another reason could be the
smaller number of fluoroquinolone-resistant E. coli strains in
our group.
Our data showed a similar level of other minor in-
fectious complications (2.91 %) in comparison with pre-
vious studies [5].
Despite the fact that the most common complications after
TRUS-Bx were haematuria (45.63 %) and haematospermia
(14.56 %), they usually did not require any treatment. It was
the infectious complications that were the most common rea-
son for readmission after TRUS-Bx.
Considering the number of prostate biopsies taken world-
wide, the burden of the management of infectious complica-
tions is very significant. Exploring possible influencing fac-
tors is very important. We have confirmed that there was nei-
ther correlation between infectious complications and the
numbers of cores collected during prostate biopsy nor the
history of previous TRUS-Bx. Steensels et al. reported a sim-
ilar conclusion that repeat biopsy alone is not a risk factor for
the faecal carriage of fluoroquinolone-resistant strains [15].
However, the influence of the number of biopsy cores collect-
ed during prostate biopsy on developing complications seems
to be controversial. There are some reports describing the
number of biopsy cores as a risk factor influencing the devel-
opment of infectious complications, as well as haematuria,
haematospermia and rectal bleeding [33–37], whereas the ma-
jority of studies did not detect an association between compli-
cation rates and this factor [38–44].
Several limitations need to be considered in discussing the
results of this study. Follow-up contact was limited, for the
most part, to telephone interviews. This could be a potential
source of bias in the interpretation of post-biopsy complica-
tions, even though the response rate of telephone follow-up
was high.
Another limitation of the study was the omission of
feverishness/low-grade fever (37–38 °C) in the telephone
follow-up questions. Consideration of this condition, which
may potentially be the cause of the patient’s discomfort, could
possibly increase the complications rate. However, low-grade
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fever would hardly be recognised as an infectious complica-
tion. Non-infectious minor post-operative complications ap-
pear to cause feverishness, whereas higher temperature values
usually concern an infectious cause.
Conclusions
Despite the limitations, this study shows that resistance
to fluoroquinolones and multiple drug resistance (MDR)
of Escherichia coli strains isolated from rectal swab
cultures prior to transrectal ultrasound-guided prostate
biopsy (TRUS-Bx) are the risk factors for readmission
and infectious complications after this procedure. Rectal
swab cultures can identify bacterial strains which are a
potential source of infectious complications after pros-
tate biopsy and may be used for the planning of a
targeted and empiric antimicrobial prophylaxis.
However, the results of this research has, so far, not con-
firmed the recent phenomenon of increasing prevalence of
fluoroquinolone-resistant E. coli strains and the associated
increase of severe infectious complications.
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